Canton Strategic Holdings (CNTN) FY2025 10-K Risk Factors: 40 New, 29 Dropped

What the changes say

Canton Strategic Holdings pivoted from biotechnology to a digital asset treasury strategy holding Canton Coin (CC).

What changed since the prior 10-K

New

NewRisks Related to Our CC Strategy and Holdings
We are shifting our business strategy from biotechnology operations to a CC treasury strategy, which represents a fundamental change in our risk profile and may not be successful
Shifting strategy from biotechnology to a CC digital asset treasury risks distracting management and delaying biotech revenue streams.
NewRisks Related to Our CC Strategy and Holdings
We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition, and results of operations
Uncertain state and federal regulations, including SEC enforcement, could adversely affect the price and transferability of CC.
NewRisks Related to Our CC Strategy and Holdings
Our digital asset treasury exposure to CC involves novel and significant risks, including market volatility, accounting, regulatory, custody, cybersecurity, liquidity and reputational risks, which could have a material adverse effect on our business, results of operations and financial condition
Holding CC exposes us to extreme price volatility, GAAP fair value earnings fluctuations, and third-party custodial dependencies.
NewRisks Related to Our CC Strategy and Holdings
Failure of the Canton Network to achieve broad market acceptance would materially and adversely affect our business, financial condition, and results of operations
Adoption of the Canton Network by major financial institutions is uncertain due to its permissioned, compliance-oriented design.
NewRisks Related to Our CC Strategy and Holdings
Regulatory change reclassifying CC as a security could lead to our classification as an “investment company” under the Investment Company Act of 1940, as amended, or the 1940 Act, and could adversely affect the market price of CC and the market price of our common stock
If CC is reclassified as a security, we could be deemed an investment company under the Investment Company Act of 1940.
NewRisks Related to Our CC Strategy and Holdings
Our financial results and the market price of our common stock may be affected by the prices of CC
Declines in the fair value of CC below our carrying value could require material write-downs and cause earnings volatility.
NewRisks Related to Our CC Strategy and Holdings
The concentration of CC ownership could increase the risk of malicious activity, including potential attacks on the Canton Network
Concentration of CC ownership among founders and approved validators creates risks of malicious activity and transaction price manipulation.
NewRisks Related to Our CC Strategy and Holdings
We face risks relating to the custody of our CC tokens, including the loss or destruction of private keys required to access our CC tokens and cyberattacks or other data loss relating to our CC tokens, including smart contract related losses and vulnerabilities
Custodying CC across multiple providers who share similar infrastructure creates systemic risks of private key loss or cyberattacks.
NewRisks Related to Our CC Strategy and Holdings
We will operate in a highly competitive environment and will compete against companies and other entities with similar strategies, including companies with significant CC holdings and spot exchange traded funds and spot ETPs for digital assets
We face intense competition from other public CC-holding companies, spot exchange-traded funds, and ETPs.
NewRisks Related to Our CC Strategy and Holdings
The availability of spot ETPs for CC and other digital assets may adversely affect the market price of our listed securities
Availability of spot ETPs for CC may reduce investor demand for our common stock, lowering its market price.
NewRisks Related to Our CC Strategy and Holdings
As a result of the foregoing factors, availability of spot ETPs for CC and other digital assets could have a material adverse effect on the market price of our listed securities
Security breaches or lost private keys at our institutional custodians could result in the total loss of our CC holdings.
NewRisks Related to Our CC Strategy and Holdings
We face other risks related to our CC digital asset treasury reserve business model
Our CC treasury model exposes us to enhanced regulatory oversight, potential validator reward disruptions, and litigation risks.
NewRisks Related to Our CC Strategy and Holdings
Negative developments in the cryptocurrency industry — including fraud, cybercrime or platform failures — may result in unfavorable publicity and could impact investor sentiment with respect to us even if we are not directly involved in any of the reported events
NewRisks Related to Our CC Strategy and Holdings
Our CC holdings are and will be less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents
NewRisks Related to Our CC Strategy and Holdings
If we elect to use derivative instruments to hedge the price risk of holding CC, such derivatives are highly volatile and subject to market and liquidity risks, which could negatively impact our digital asset treasury strategy
NewRisks Related to Our CC Strategy and Holdings
We will be exposed to the default risk of our clearing broker if we hedge the price risk of CC through the purchase of futures contracts
NewRisks Related to Our CC Strategy and Holdings
We face risks relating to the use of third-party exchanges in connection with our CC strategy
NewRisks Related to Our CC Strategy and Holdings
Future developments regarding the treatment of crypto assets for U.S. and foreign tax purposes could adversely impact our business
NewRisks Related to Our CC Strategy and Holdings
We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers
NewRisks Related to Our Therapeutic Candidates Developments
Delays, suspension, or termination of clinical trials could limit our ability to commercialize products and affect our business prospects
NewRisks Related to Our Therapeutic Candidates Developments
The outcome of pre-clinical testing and early clinical trials may not be predictive of later success
NewRisks Related to Our Therapeutic Candidates Developments
Adverse side effects or safety risks could delay or preclude approval, cause us to suspend clinical trials, or result in negative consequences following any marketing approval
NewRisks Related to Our Therapeutic Candidates Developments
We may not achieve our development milestones on our projected timelines
NewRisks Related to Our Therapeutic Candidates Developments
Product liability claims could materially harm our business
NewRisks Related to Our Therapeutic Candidates Developments
Breakthrough Therapy designation may not lead to faster development, review, or approval
NewRisks Related to Our Therapeutic Candidates Developments
We rely on third parties to conduct our pre-clinical studies and clinical trials, and their failure to perform could substantially harm our business
NewRisks Related to Our Therapeutic Candidates Developments
We rely on third-party manufacturers for our drug candidates and expect to continue doing so for commercialization
NewRisks Related to Our Therapeutic Candidates Developments
We may not be successful in commercializing one or more of our drug candidates
NewRisks Related to Our Therapeutic Candidates Developments
Our drug candidates and the activities associated with the development and commercialization are subject to comprehensive regulation by the FDA and other regulatory agencies
NewRisks Related to Our Therapeutic Candidates Developments
Any approved drug candidates may be subject to post-marketing requirements, restrictions, or withdrawal, and noncompliance could result in penalties
NewRisks Related to Our Therapeutic Candidates Developments
Regulators, including the FDA and the Department of Justice, closely monitor post-approval promotion. Promotion outside the approved labeling can trigger enforcement under the FDCA and other laws, including the False Claims Act, and may result in civil or criminal liability
NewRisks Related to Our Operations and Financial Conditions
Due to our limited operating history and the concentration of our CC token holdings, it will be difficult to evaluate our business and future prospects, and we may not be able to achieve or maintain profitability in any given period
NewRisks Related to Our Operations and Financial Conditions
We will need additional financing in the future, which may not be available when needed or may be costly and dilutive
NewRisks Related to Our Operations and Financial Conditions
Our senior management team has limited experience managing and operating a U.S. public company
NewRisks Related to Our Operations and Financial Conditions
Unrealized fair value gains on the Company’s CC holdings may cause the Company to become subject to the corporate alternative minimum tax under the Inflation Reduction Act of 2022
NewRisks Related to Cybersecurity, Information Technology, and Intellectual Property
Our business and operations would be adversely impacted in the event of a failure or interruption of our information technology infrastructure or as a result of a cybersecurity attack
NewRisks Related to Cybersecurity, Information Technology, and Intellectual Property
If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, our business could be harmed
NewRisks Related to Our Securities and Being a Public Company
Sales of our common stock, or the perception that such sales may occur, could cause the market price of our common stock to fall
NewRisks Related to Our Securities and Being a Public Company
We have issued warrants exercisable for our securities, which if exercised, would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders
NewRisks Related to Our Securities and Being a Public Company
If we fail to maintain an effective system of internal controls, we may not be able to accurately determine our financial results or prevent fraud. As a result, our stockholders could lose confidence in our financial results, which could harm our business and the value of our common stock

Dropped

DroppedRisks Related to Our Financial Position and Need for Additional Capital
We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance
Limited operating history as a clinical-stage biopharmaceutical company.
DroppedRisks Related to Our Financial Position and Need for Additional Capital
Finding appropriate biomarkers for our potential drug candidates could limit our commercialization prospects and cause our losses to continue
Failure to find appropriate biomarkers for drug candidates.
DroppedRisks Related to Our Financial Position and Need for Additional Capital
Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several milestones relating to the discovery, development and commercialization of our product candidates
DroppedRisks Related to Our Financial Position and Need for Additional Capital
We will require substantial additional funding. If we are unable to raise capital on favorable terms when needed, we could be forced to curtail, delay or discontinue our research or drug development programs or any future commercialization efforts
Milestones relating to discovery, development, and commercialization of product candidates.
DroppedRisks Related to Our Financial Position and Need for Additional Capital
Management has performed an analysis and concluded that there exists a substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing on terms acceptable to us, if at all
Need for substantial additional funding to advance drug candidates like TH104.
DroppedRisks Related to the Discovery and Development of Our Product Candidates
Any delays in the commencement or completion, or termination or suspension, of our ongoing, planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects
Substantial doubt about our ability to continue as a going concern.
DroppedRisks Related to the Discovery and Development of Our Product Candidates
The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, European Medicines Agency (“EMA”) or other comparable foreign regulatory authorities
DroppedRisks Related to the Discovery and Development of Our Product Candidates
If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented
DroppedRisks Related to the Discovery and Development of Our Product Candidates
Any of these events could prevent us from achieving or maintaining market acceptance of our drug candidates, if approved, and could significantly harm our business, financial condition, results of operations and prospects
Delays or suspensions in clinical trials and FDA submissions.
DroppedRisks Related to the Discovery and Development of Our Product Candidates
If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business
Pre-clinical and early clinical trial outcomes not predicting later trial success.
DroppedRisks Related to the Discovery and Development of Our Product Candidates
Pandemics, such as COVID-19, may adversely impact our business, results of operations, financial condition, liquidity and cash flows and that of our clients
DroppedRisks Related to the Discovery and Development of Our Product Candidates
We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success
Delays or difficulties in enrolling patients in clinical trials.
DroppedRisks Related to the Discovery and Development of Our Product Candidates
We may not be successful in our efforts to design additional potential drug candidates
Failure to achieve or maintain market acceptance of drug candidates.
DroppedRisks Related to the Discovery and Development of Our Product Candidates
If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting the U.S. healthcare reform, our business may be harmed
Product liability claims exceeding insurance coverage.
DroppedRisks Related to the Discovery and Development of Our Product Candidates
The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and if we are found to have improperly promoted off-label uses of our drugs or drug candidates, if approved, we may become subject to significant liability
DroppedRisks Related to the Discovery and Development of Our Product Candidates
A Breakthrough Therapy designation by the FDA for our drug candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our drug candidates will receive marketing approval
Impact of pandemics like COVID-19 on operations.
DroppedRisks Related to Our Reliance on Third Parties
Our current and anticipated future dependence upon others for the manufacture of our drug candidates or products may adversely affect our future profit margins and our ability to commercialize any products that obtain marketing approval on a timely and competitive basis
Resource allocation risks from prioritizing specific drug candidates.
DroppedRisks Related to Commercialization of Our Drug Candidates
Even if we are successful in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one or more of our drug candidates
DroppedRisks Related to Managing Our Business and Operations
We may encounter difficulties in managing our growth, which could adversely affect our operations
DroppedRisks Related to Managing Our Business and Operations
Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs
DroppedRisks Related to Managing Our Business and Operations
Significant disruptions of information technology systems or breaches of data security could adversely affect our business
DroppedRisks Related to Managing Our Business and Operations
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
DroppedRisks Related to Managing Our Business and Operations
The increasing use of social media platforms presents new risks and challenges
DroppedRisks Related to Managing Our Business and Operations
The estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all
DroppedRisks Related to Managing Our Business and Operations
Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
DroppedRisks Related to Managing Our Business and Operations
Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business
DroppedRisks Related to Managing Our Business and Operations
Changes in U.S. tax law could adversely affect our financial condition and results of operations
DroppedRisks Related to Our Common Stock
If we fail to comply with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted
DroppedRisks Related to Our Common Stock
Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall

Reworded

98% rewrittenRisks Related to Our Therapeutic Candidates Developments
We are substantially dependent on the success of our product candidates. If we are unable to complete development of, obtain approval for, or successfully commercialize our product candidates, our business may be harmed
Updated dependencies on product candidate development and added factors beyond our control causing commercialization delays.
Was: We are substantially dependent on the success of our product candidates. If we are unable to complete development of, obtain approval for and commercialize our product candidates for one or more indications in a timely manner, our business may be harmed
97% rewrittenRisks Related to Our Therapeutic Candidates Developments
Healthcare reform initiatives in the United States may impact our business and results of operations
Expanded details on the Affordable Care Act's Medicaid rebates and manufacturer taxes.
96% rewrittenRisks Related to Our Therapeutic Candidates Developments
We are subject to healthcare laws and regulations
Added specific healthcare laws including HIPAA, the federal Physician Payments Sunshine Act, and state transparency laws.
96% rewrittenRisks Related to Our Therapeutic Candidates Developments
Our pipeline is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult to predict development timelines, costs, and regulatory approval
Refined language regarding the novel mechanism of our drug candidates and clinical trial uncertainties.
Was: Our pipeline is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval
92% rewrittenRisks Related to Our Securities and Being a Public Company
The price of our stock may be volatile, and you could lose all or part of your investment
Added stock volatility triggers including interest rate hikes, indebtedness, and shareholder actions.
88% rewrittenRisks Related to Our Therapeutic Candidates Developments
We face significant competition from companies that may develop more effective, safer, or less expensive products
Specified rare diseases, inflammatory conditions, and oncology as highly competitive areas with major pharmaceutical rivals.
Was: We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted
86% rewrittenRisks Related to Our Therapeutic Candidates Developments
We may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates
Clarified Orphan Drug Act exclusivity terms and competing applications.
80% rewrittenRisks Related to Our Therapeutic Candidates Developments
Failure to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad
Retained prior year risk text regarding foreign marketing and reimbursement approvals.
78% rewrittenRisks Related to Our Therapeutic Candidates Developments
Interim, topline, and preliminary clinical trial data may change as more patient data becomes available and are subject to audit and verification procedures
Was: Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available, and are subject to audit and verification procedures that could result in material changes in the final data
73% rewrittenRisks Related to Cybersecurity, Information Technology, and Intellectual Property
Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
68% rewrittenRisks Related to Cybersecurity, Information Technology, and Intellectual Property
If we fail to comply with our obligations in license arrangements with third parties, we could lose rights that are important to our business
Was: If we fail to comply with our obligations in our future intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business
67% rewrittenRisks Related to Our Therapeutic Candidates Developments
The development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals for our drug candidates on a timely basis, or at all
61% rewrittenRisks Related to Our Therapeutic Candidates Developments
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business
58% rewrittenRisks Related to Our Therapeutic Candidates Developments
Our failure to find third party collaborators to assist or share in the costs of drug development could materially harm our business, financial condition and results of operations
56% rewrittenRisks Related to Our Securities and Being a Public Company
We could be subject to securities class action litigation
51% rewrittenRisks Related to Our Therapeutic Candidates Developments
Our current and future products may never achieve significant commercial market acceptance
32% rewrittenRisks Related to Our Therapeutic Candidates Developments
We currently depend on a sole source supplier and manufacturer for the active ingredient in our product candidates and the inability to obtain the active ingredient for our product candidates as required could harm our business
28% rewrittenRisks Related to Our Operations and Financial Conditions
We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability

All 73 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our CC Strategy and Holdings

01We are shifting our business strategy from biotechnology operations to a CC treasury strategy, which represents a fundamental change in our risk profile and may not be successfulNew
02We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition, and results of operationsNew
03Our digital asset treasury exposure to CC involves novel and significant risks, including market volatility, accounting, regulatory, custody, cybersecurity, liquidity and reputational risks, which could have a material adverse effect on our business, results of operations and financial conditionNew
04Failure of the Canton Network to achieve broad market acceptance would materially and adversely affect our business, financial condition, and results of operationsNew
05Regulatory change reclassifying CC as a security could lead to our classification as an “investment company” under the Investment Company Act of 1940, as amended, or the 1940 Act, and could adversely affect the market price of CC and the market price of our common stockNew
06Our financial results and the market price of our common stock may be affected by the prices of CCNew
07The concentration of CC ownership could increase the risk of malicious activity, including potential attacks on the Canton NetworkNew
08We face risks relating to the custody of our CC tokens, including the loss or destruction of private keys required to access our CC tokens and cyberattacks or other data loss relating to our CC tokens, including smart contract related losses and vulnerabilitiesNew
09We will operate in a highly competitive environment and will compete against companies and other entities with similar strategies, including companies with significant CC holdings and spot exchange traded funds and spot ETPs for digital assetsNew
10The availability of spot ETPs for CC and other digital assets may adversely affect the market price of our listed securitiesNew
11As a result of the foregoing factors, availability of spot ETPs for CC and other digital assets could have a material adverse effect on the market price of our listed securitiesNew
12We face other risks related to our CC digital asset treasury reserve business modelNew
13Negative developments in the cryptocurrency industry — including fraud, cybercrime or platform failures — may result in unfavorable publicity and could impact investor sentiment with respect to us even if we are not directly involved in any of the reported eventsNew
14Our CC holdings are and will be less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalentsNew
15If we elect to use derivative instruments to hedge the price risk of holding CC, such derivatives are highly volatile and subject to market and liquidity risks, which could negatively impact our digital asset treasury strategyNew
16We will be exposed to the default risk of our clearing broker if we hedge the price risk of CC through the purchase of futures contractsNew
17We face risks relating to the use of third-party exchanges in connection with our CC strategyNew
18Future developments regarding the treatment of crypto assets for U.S. and foreign tax purposes could adversely impact our businessNew
19We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisersNew

Risks Related to Our Therapeutic Candidates Developments

20We are substantially dependent on the success of our product candidates. If we are unable to complete development of, obtain approval for, or successfully commercialize our product candidates, our business may be harmed98% rewritten
21Our pipeline is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult to predict development timelines, costs, and regulatory approval96% rewritten
22Delays, suspension, or termination of clinical trials could limit our ability to commercialize products and affect our business prospectsNew
23The outcome of pre-clinical testing and early clinical trials may not be predictive of later successNew
24Interim, topline, and preliminary clinical trial data may change as more patient data becomes available and are subject to audit and verification procedures78% rewritten
25Adverse side effects or safety risks could delay or preclude approval, cause us to suspend clinical trials, or result in negative consequences following any marketing approvalNew
26We may not achieve our development milestones on our projected timelinesNew
27Product liability claims could materially harm our businessNew
28Our current and future products may never achieve significant commercial market acceptance51% rewritten
29We face significant competition from companies that may develop more effective, safer, or less expensive products88% rewritten
30We are subject to healthcare laws and regulations96% rewritten
31We may not be able to obtain or maintain Fast Track designation or accelerated approval for our drug candidates
32We may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates86% rewritten
33Breakthrough Therapy designation may not lead to faster development, review, or approvalNew
34We rely on third parties to conduct our pre-clinical studies and clinical trials, and their failure to perform could substantially harm our businessNew
35We rely on third-party manufacturers for our drug candidates and expect to continue doing so for commercializationNew
36We currently depend on a sole source supplier and manufacturer for the active ingredient in our product candidates and the inability to obtain the active ingredient for our product candidates as required could harm our business32% rewritten
37Our failure to find third party collaborators to assist or share in the costs of drug development could materially harm our business, financial condition and results of operations58% rewritten
38We may not be successful in commercializing one or more of our drug candidatesNew
39Our drug candidates and the activities associated with the development and commercialization are subject to comprehensive regulation by the FDA and other regulatory agenciesNew
40We have no experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of any of our drug candidates
41We may seek to collaborate with a third party to market our drugs or may seek to market and sell our drugs by ourselves. If we seek to collaborate with a third party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to us
42The development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals for our drug candidates on a timely basis, or at all67% rewritten
43Failure to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad80% rewritten
44Any approved drug candidates may be subject to post-marketing requirements, restrictions, or withdrawal, and noncompliance could result in penaltiesNew
45Regulators, including the FDA and the Department of Justice, closely monitor post-approval promotion. Promotion outside the approved labeling can trigger enforcement under the FDCA and other laws, including the False Claims Act, and may result in civil or criminal liabilityNew
46Healthcare reform initiatives in the United States may impact our business and results of operations97% rewritten
47If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business61% rewritten
48If we do not obtain patent term extension for any drug candidates we may develop, our business may be materially harmed

Risks Related to Our Operations and Financial Conditions

49We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability28% rewritten
50Due to our limited operating history and the concentration of our CC token holdings, it will be difficult to evaluate our business and future prospects, and we may not be able to achieve or maintain profitability in any given periodNew
51We will need additional financing in the future, which may not be available when needed or may be costly and dilutiveNew
52Our senior management team has limited experience managing and operating a U.S. public companyNew
53Unrealized fair value gains on the Company’s CC holdings may cause the Company to become subject to the corporate alternative minimum tax under the Inflation Reduction Act of 2022New

Risks Related to Cybersecurity, Information Technology, and Intellectual Property

54Our business and operations would be adversely impacted in the event of a failure or interruption of our information technology infrastructure or as a result of a cybersecurity attackNew
55Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our drugs
56We or our licensors may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful
57Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business73% rewritten
58Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities
59If we fail to comply with our obligations in license arrangements with third parties, we could lose rights that are important to our business68% rewritten
60If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, our business could be harmedNew
61We may not be able to protect our intellectual property and proprietary rights

Risks Related to Our Securities and Being a Public Company

62The price of our stock may be volatile, and you could lose all or part of your investment92% rewritten
63Sales of our common stock, or the perception that such sales may occur, could cause the market price of our common stock to fallNew
64We have issued warrants exercisable for our securities, which if exercised, would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholdersNew
65We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
66Our Certificate of Incorporation, Bylaws and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline
67Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price
68Market and economic conditions may negatively impact our business, financial condition and share price
69We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors
70Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters
71If we fail to maintain an effective system of internal controls, we may not be able to accurately determine our financial results or prevent fraud. As a result, our stockholders could lose confidence in our financial results, which could harm our business and the value of our common stockNew
72If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline
73We could be subject to securities class action litigation56% rewritten

Other Canton Strategic Holdings 10-Ks

FY2024 10-K risk factors
62 risks
Clinical-stage biopharmaceutical company with no approved products, no revenue, and substantial accumulated deficit.
Filed Mar 26, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.